Taxonomic studies of the subgenus Helcocyrtomyia: II. series Vexator (Diptera, Psychodidae, Phlebotominae)

Continuing to review the subgenus Helcocyrtomyia (Diptera, Psychodidae, Phlebotomiane) some specimens of sandflies from the vexator series were examined. Taxonomic remarks, geographic distribution and drawings of those species are presented.

MMP-9 as predictive factor for response and progression free survival in breast cancer patients treated with bevacizumab and pegylated liposomal doxorubicin. A multicenter, single-arm phase II trial (SAKK24/06). On behalf of the Swiss Group for Clinical Cancer Research (SAKK).

The benefit of bevacizumab (Bv) has been shown in different tumors including colorectal cancer, renal cancer, pulmonary non-small cell cancer and also breast cancer. However to date, there is no established test evaluating the angiogenic status of a patient and monitoring the effects of anti-angiogenic treatments. Tumor angiogenesis is the result of a balance between multiple pro- and anti¬angiogenic molecules. There is very little published clinical data exploring the impact of the anti-angiogenic therapy on the different angiogenesis-related molecules and the potential role of these molecules as prognostic or predictive factors.

El teatre a les societats particulars de Barcelona durant els anys de la Primera Guerra Mundial (1914-1918). El CADCI i l’Ateneu Obrer del districte II

Aquest treball és una primera aproximació al magmàtic món del teatre societari barceloní de principis de segle XX. Vol ser una radiografia, primer, en forma d’estat de la qüestió general, i després, en forma d’anàlisi de dos casos concrets, el CADCI i l’Ateneu Obrer del districte II, de tots els aspectes que engloba el fet teatral en aquests espais: des dels repertoris al funcionament de les companyies, passant per la recepció, el paper del públic o la importància del teatre com a eina política i de transmissió generacional del coneixement. Tot això en el context d’uns anys de crisi del món teatral, en general, i del teatre català, en particular.

Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).

BACKGROUND: Sunitinib (SU) is a multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity. The objective of this trial was to demonstrate antitumor activity of continuous SU treatment in patients with hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Key eligibility criteria included unresectable or metastatic HCC, no prior systemic anticancer treatment, measurable disease, and Child-Pugh class A or mild Child-Pugh class B liver dysfunction. Patients received 37.5 mg SU daily until progression or unacceptable toxicity. The primary endpoint was progression-free survival at 12 weeks (PFS12). RESULTS: Forty-five patients were enrolled. The median age was 63 years; 89% had Child-Pugh class A disease and 47% had distant metastases. PFS12 was rated successful in 15 patients (33%; 95% confidence interval, 20%-47%). Over the whole trial period, one complete response and a 40% rate of stable disease as the best response were achieved. The median PFS duration, disease stabilization duration, time to progression, and overall survival time were 1.5, 2.9, 1.5, and 9.3 months, respectively. Grade 3 and 4 adverse events were infrequent. None of the 33 deaths were considered drug related. CONCLUSION: Continuous SU treatment with 37.5 mg daily is feasible and has moderate activity in patients with advanced HCC and mild to moderately impaired liver dysfunction. Under this trial design (>13 PFS12 successes), the therapy is considered promising. This is the first trial describing the clinical effects of continuous dosing of SU in HCC patients on a schedule that is used in an ongoing, randomized, phase III trial in comparison with the current treatment standard, sorafenib (ClinicalTrials.gov identifier, NCT00699374).

Pilotage des écoles du secondaire II en Suisse romande : quels outils de gestion pour favoriser l'amélioration continue ?

Le projet « Pilotage des écoles du secondaire II en Suisse romande : quels outils de gestion pour favoriser l'amélioration continue ? » vise à identifier les outils, méthodes et initiatives développés par les Directions de l'instruction publique et les établissements de formation pour favoriser l'amélioration continue. Dans ce cadre, le Centre suisse de formation continue des professeurs de l'enseignement secondaire (ci-après CPS) a mené une enquête auprès de 38 personnes (22 représentants des directions d'écoles, 12 représentants des Services de l'enseignement secondaire II et quatre spécialistes). Les réponses fournies par les personnes sondées sont synthétisées dans le présent rapport.